

University of Groningen

## Treatment outcomes in ANCA-associated vasculitis

Hessels, Arno

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Hessels, A. (2019). *Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **Treatment outcomes in ANCA-associated vasculitis**

Determinants of efficacy and toxicity

**Arno Christiaan Hessels**

Arno Hessels  
Treatment outcomes in ANCA-associated vasculitis:  
Determinants of efficacy and toxicity  
Dissertation University of Groningen, The Netherlands

Financial support by  
the University of Groningen  
University Medical Center Groningen  
Graduate School for Drug Exploration (GUIDE)  
Vasculitis Stichting  
are gratefully acknowledged.

ISBN:  
978-94-6375-159-9 (printed version)  
978-94-034-1493-5 (digital version)

Cover design: Kristina Hristova  
Lay-out: Kristina Hristova  
Printed by: Ridderprint B.V., Ridderkerk, the Netherlands

Further financial support for the printing of this thesis was kindly provided by  
Vifor Fresenius Medical Care Renal Pharma Ltd.

©A.C. Hessels 2018  
All rights reserved. No part of this publication may be reproduced, copied,  
modified, stored in a retrieval system or transmitted without the prior permission  
in writing from the author.



rijksuniversiteit  
 groningen

# Treatment outcomes in ANCA-associated vasculitis

Determinants of efficacy and toxicity

## Proefschrift

ter verkrijging van de graad van doctor aan de  
Rijksuniversiteit Groningen  
op gezag van de  
rector magnificus prof. dr. E. Sterken  
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 20 maart 2019 om 16:15 uur

door

**Arno Christiaan Hessels**

geboren op 28 juli 1992  
te Zwolle

**Promotor**

Prof. dr. C. A. Stegeman

**Copromotores**

Dr. A. Rutgers

Dr. J. S. F. Sanders

**Beoordelingscommissie**

Prof. dr. T. van Gelder

Prof. dr. T. P. Links

Prof. dr. S. P. Berger

---

# Contents

Chapter 1	Introduction: current challenges in the treatment of ANCA-associated vasculitis	7
<b>Part 1 Pharmacogenetics</b>		
Chapter 2	Review: gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis	23
Chapter 3	Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study	45
Chapter 4	Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor	67
<b>Part 2 Characterizing treatment outcomes</b>		
Chapter 5	Geographic differences in clinical presentation and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: role of antibody specificity	91
Chapter 6	Azathioprine hypersensitivity syndrome in a cohort of antineutrophil cytoplasmic antibody-associated vasculitis patients	105
Chapter 7	Leg muscle strength is reduced and is associated with physical quality of life in antineutrophil cytoplasmic antibody-associated vasculitis	119
Chapter 8	Summary and future perspectives	139
	Nederlandse samenvatting	151
	Dankwoord	159
	About the author	163

